Unlock the Potential of PROTAC Technology with Medicilon
State of the art PROTAC Platform
Overview
What Are PROTACs?
PROTACs are small molecules designed to degrade specific disease-associated proteins. Unlike traditional drug inhibitors, PROTACs leverage the cell’s ubiquitin-proteasome system to target and degrade proteins that were once considered “undruggable.” This innovative mechanism offers vast therapeutic opportunities for diseases such as cancer, neurodegeneration, and more.
Why PROTAC Matters?
Enhanced Selectivity & Efficacy
Targeted degradation ensures precision by sparing healthy proteins
Resistance Mitigation
Effectively combats mutated proteins that evade traditional inhibitors
Broad Applications
From oncology to autoimmune disorders, PROTACs are reshaping drug discovery
our Promise
Medicilon’s Comprehensive PROTAC Drug Discovery Platform
Medicilon provides cutting-edge PROTAC solutions through its state-of-the-art platform, tailored to accelerate your drug discovery process.
POI Ligands
Our team of over 1,200 experienced chemists specializes in designing high-affinity warheads with structural validation techniques like SPR and ITC, ensuring optimized ligand development
Linker Chemistry
With over 300 validated linkers, including PEG linkers and hydrophobic variants, our solutions are designed to optimize PROTAC stability, solubility, and degradation efficiency
E3 Ligase Binders
Comprehensive expertise in popular E3 ligases like CRBN and VHL ensures target-specific degradation solutions
Expert Chemistry Development
Preclinical Services: In Vitro and In Vivo Evaluation
In Vitro Assays
Advanced degradation assays, including HiBiT and Western blot, assess dose-response relationships.
Case highlight: IRAK4 degrader achieved a robust DC50 of 42 nM
Figure 1A. IRAK4 degradation dose-response (HiBiT)
Figure 1B. IRAK4 Western Blot Analysis
Figure 1C. CRBN-Dependent Mechanism
Figure 1D. Proteasome-Dependent Degradation
Figure 1E. Growth Inhibition
Figure 1. IRAK4 degrader– 1 demonstrates dose-dependent protein degradation. IRAK4 degrader-1 effectively reduces IRAK4 levels in OCI-LY10 cells (DC50 = 42nM) through CRBN-mediated proteasomal degradation.
In Vivo Proof-of-Concept
PK/PD Studies
Toxicology & Safety
END TO END Support
Key Services Offered by Medicilon
Chemistry Solutions
Custom synthesis of POI ligands, linkers, and E3 ligase binders for targeted degradation
Preclinical Support
Comprehensive evaluations, including pharmacodynamics (PD), pharmacokinetics (PK), and toxicology studies
Regulatory Assistance
IND-enabling documentation, including PK tables and degradation curves, aligned with global standards
Ready to consult Medicilon’s expertise in PROTAC?
Medicilon is ready to transform your research with its unparalleled PROTAC technology and expertise
